The efficacy of 1053-PE38 compares favorably with the several monoclonal antibodies against CD38 for targeting MM cells that are currently in clinic trials, including daratumumab from GenMab/Johnson & Johnson38 and SAR650984 from Sanofi39. The gene discussed is CD38; the disease is Miyoshi myopathy.